2021年华东医药股份有限公司一季报

Huadong Medicine Co., Ltd. The First Quarterly Report 2021 April 2021 Section I Important Declaration The Board of Directors, Board of Supervisors, directors, supervisors and senior management of Huadong Medicine Co., Ltd. (hereinafter referred to as the “Company”) hereby guarantee that the information presented in this report is authentic, accurate and complete and free of any false records, misleading statements or material omissions, and shall undertake individual and joint legal liabilities. All directors have attended the board of directors meeting to review this quarterly report. Lv Liang, the Company’s legal representative and the officer in charge of accounting, and Qiu Renbo, head of accounting department (accounting supervisor) hereby declare and guarantee that the financial statements in this quarterly report are authentic, accurate and complete. According to “Stock Listing Rules of the Shenzhen Stock Exchange”, if listed companies have both Chinese or other language version of public notice, they should ensure the content of both versions are the same. In the case of discrepancy, the originalversion in Chinese shallprevail. Section II Company Profile I. Key Accounting Data and Financial Indicators Whether the Company needs to perform retroactive adjustment or restatement of previous accounting data □Yes √ No Change of the current The current reporting period Same period last year reporting period over the same period last year Operating revenue (yuan) 8,896,632,277.36 8,598,069,911.29 3.47% Net profit attributable to shareholders of 758,380,756.56 1,147,278,457.64 -33.90% listed companies (yuan) Net profit attributable to shareholders of listed companies after deducting 695,792,411.78 856,930,262.10 -18.80% non-recurring gains/losses (yuan) Net cash flow from operating activities (yuan) 302,314,164.48 218,779,623.89 38.18% Basic earnings per share (yuan/s hare) 0.4334 0.6557 -33.90% Diluted earnings per share (yuan/share) 0.4334 0.6557 -33.90% Weighted average return on equity (ROE) 5.04% 8.89% -3.85% Change of the end of the End of the current reporting current reporting period End of last year period over the end of last year Totalassets (yuan) 26,096,806,585.74 24,201,348,154.75 7.83% Net assets attributable to shareholders of 15,266,793,123.79 14,619,821,308.60 4.43% listed companies (yuan) Items and amounts of non-recurring gains/losses √Applicable □ N/A Unit: RMB yuan Amount (from the beginning Item of the year to the end of the Note reporting period) Gains/losses on disposa lof non-current assets (including the written-off part of the accrued assets impairment reserve) 15,675.63 Government grants included in current gains/losses (excluding those closely related to operating activities, or regular government 76,459,624.41 grants) Other non-operating income or expenditure -2,351,230.65 Less:Amount affected by income tax 11,433,797.38 Amount affected by minority interest (after tax) 101,927.23 Total 62,588,344.78 -- If the Company recognizes an ite m as a non-recurring gain/loss based on the “Interpretation Announcement on Information Disclosure Criteria for Public Companies No. 1 – Non-Recurring Profit/Loss” or recognizes an item satisfying the definition of non-recurring profit/loss in the announcement as a recurring profit/loss, reasons should be specified. □Applicable √ N/A No such case during the reporting period. II. Total number of shareholders at the end of the reporting period and information of top 10 shareholders 1. Total number of shareholders of common shares and number of shareholders of preferred shares with voting rights restored, as well as information about top 10 shareholders Unit: share Tota lnumber of shareholders of Tota lnumber of shareholders of preferred shares whose voting rights common shares at the end of the 168,355 0 have been restored at the end of the reporting period reporting period (if any) Information about top 10 shareholders Number of shares Pledged or frozen Name Shareholding Number of shares held w ith sale Nature ratio held restrictions Status Number Domestic China Grand non-state-owned 41.77% 730,938,157 0 Pledged 239,970,000 Enterprises, Inc. legalperson Hangzhou Huadong State-owned lega l 15.69% 274,620,000 0 Medicine Group person Co., Ltd. Hong Kong Securities Overseas legal 1.82% 31,905,503 0 Clearing person Company Ltd. China Securities Finance Co., Ltd. Other 1.27% 22,186,818 0 Huaxia Life Insurance Co., Other 0.61% 10,713,280 0 Ltd. - own funds NationalSocia l Other 0.45% 7,926,311 0 Security Fund Portfolio 602 NationalSocia l Security Fund Other 0.34% 6,000,000 0 Portfolio 503 Basic Endowment Other 0.30% 5,253,350 0 Insurance Fund Portfolio 15041 Domestic #YangYus han 0.29% 5,000,000 0 individual Domestic #Chen Shaoming 0.22% 3,764,388 0 individual Shares held by the top 10 shareholders of Non- restricted shares Type of shares Name Number of shares he ld w it hout sale restrictions Type Number China Grand Enterprises, Inc. RMB common 730,938,157 730,938,157 shares Hangzhou Huadong Medicine RMB common 274,620,000 274,620,000 Group Co., Ltd. shares Hong Kong Securities Clearing RMB common Company Ltd. 31,905,503 31,905,503 shares RMB common China Securities Finance Co., Ltd. 22,186,818 22,186,818 shares Huaxia Life Ins urance Co., Ltd. - RMB common 10,713,280 10,713,280 own funds shares NationalSocia lSecurity Fund RMB common 7,926,311 7,926,311 Portfolio 602 shares NationalSocia lSecurity Fund RMB common Portfolio 503 6,000,000 6,000,000 shares Basic Endowment Insurance Fund